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People with persistently asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-31 
CoV-2) infection experience no symptoms throughout the course of infection, while pre-32 
symptomatic individuals report symptoms attributable to the virus. Transmission of SARS-CoV-33 
2 from individuals without symptoms contributes to pandemic spread, but the extent of 34 
transmission from persistently asymptomatic individuals remains unknown. We describe three 35 
methodological issues that hinder attempts to estimate this proportion. First, incomplete 36 
symptom assessment likely overestimates the asymptomatic fraction. Second, studies with 37 
inadequate follow-up misclassify pre-symptomatic individuals. Third, serological studies may 38 
identify people with previously unrecognized infection, but reliance on poorly defined antibody 39 
responses and retrospective symptom assessment may result in misclassification. We provide 40 
recommendations regarding definitions, detection, documentation and follow-up to improve the 41 
identification and evaluation of people with persistently asymptomatic SARS-CoV-2 infection 42 
and their contacts. Accurate characterisation of the persistently asymptomatic fraction may shed 43 
light on COVID-19 pathogenesis, transmission dynamics, and inform public health responses.  44 




Among the immense challenges of the coronavirus disease 2019 (COVID-19) pandemic are 46 
mitigating viral spread and understanding the spectrum of illness severity, both of which depend 47 
on accurate descriptions of the diverse clinical presentations of SARS-CoV-2 infection. Control 48 
of spread in particular has been limited by the variable incubation period,1 well documented pre-49 
symptomatic transmission2 with approximately 25-40% of transmission occurring before the 50 
onset of symptoms,3 and heterogeneous transmission dynamics, where clusters and 51 
superspreading events play a major role in propagating the pandemic, while many infected 52 
individuals lead to no subsequent cases.4-6 Despite over 75,000 peer-reviewed and preprint 53 
publications about SARS-CoV-2 and COVID-19 since January 2020, the size and characteristics 54 
of the persistently asymptomatic fraction remain poorly understood.  55 
 56 
A person with asymptomatic SARS-CoV-2 infection has laboratory confirmed SARS-CoV-2 57 
with no symptoms at all throughout the duration of infection whereas a symptomatic person 58 
reports symptoms attributable to SARS-CoV-2. Defining the proportion of SARS-CoV-2 59 
infection that is truly asymptomatic will help to better characterise the COVID-19 illness 60 
severity spectrum, pathogenesis, transmissibility, and immunity, and will inform control policies. 61 
Systematic reviews that only include studies with sufficient time to exclude pre-symptomatic 62 
infection have estimated the percentage of SARS-CoV-2 infections that remain completely free 63 
of symptoms at 20% (95% confidence interval, CI 17-25%) and 14% (95% CI 5-24%).7,8 The 64 
individual studies included in these reviews rarely estimated an asymptomatic fraction greater 65 
than 50%. The range of estimates of asymptomatic SARS-CoV-2 reported in studies that used a 66 
wider variety of study designs goes from as low as 4% to over 80%, (Table 1).9,10  67 




[Table 1] 69 
 70 
There are three main reasons for ongoing confusion about the asymptomatic population. First, 71 
investigators have not yet developed a consistent case definition, meaning that symptom 72 
assessments differ substantially between studies and over time, with minor or atypical symptoms 73 
almost certainly missed in the earliest descriptions. Second, cross-sectional studies that assess 74 
symptoms at a single time point, or studies with a short follow up period, may incorrectly 75 
categorise individuals as asymptomatic when they are actually pre- or post-symptomatic.21,22 76 
Third, the time course and durability of the SARS-CoV-2 antibody response remain poorly 77 
understood, so there may be major limitations when using serological surveys, particularly when 78 
they are coupled with retrospective clinical history, to estimate the asymptomatic fraction.  79 
 80 
This article summarises these limitations, using examples from studies that have reported on 81 
asymptomatic SARS-CoV-2 infections (Table 1), and gives recommendations for future studies 82 
that will describe this important subset of individuals.  83 
 84 
1. Lack of consistent reporting of symptoms 85 
Our understanding of the possible clinical presentations of SARS-CoV-2 infection has evolved 86 
since the beginning of the pandemic and many studies that report an asymptomatic proportion of 87 
patients have not completely described or assessed COVID-19 symptoms based on what we 88 
know now. The first large descriptive studies of hospitalized patients with COVID-19 from 89 
China in January 2020, used information extracted from medical records and reported that the 90 
Towards an Accurate and Systematic Characterization of Persistently Asymptomatic Infection 
with SARS-CoV-2 
 5 
most common symptoms were fever, cough, fatigue and myalgia.23,24 Gastrointestinal symptoms 91 
were uncommon in those case series, though now they are more widely recognised and some 92 
reports suggest they may occur in up to half of individuals.25,26 Anosmia and dysgeusia were first 93 
documented in March 2020, may be more prevalent in milder cases,27,28 and are strongly 94 
associated with SARS-CoV-2 infection.19 A large study using a symptom tracking smartphone 95 
application found that it became more common for individuals with COVID-19 to report 96 
anosmia or dysgeusia in the UK after the association of these symptoms with infection was 97 
reported widely in the media.19,27 98 
 99 
Many studies have used an unclear or uncomprehensive method of symptom ascertainment, 100 
making it hard to interpret the reported frequency of symptoms. Information extracted 101 
retrospectively from medical records or reports that rely upon spontaneous reporting by study 102 
participants will likely underestimate the frequency of mild or atypical symptoms. In a cohort of 103 
147 individuals diagnosed with SARS-CoV-2 infection at homeless shelters in Boston, 88% 104 
(129/147) were classified as asymptomatic when asked only about a narrow range of symptoms 105 
that included a “history of cough and shortness of breath.” They were also given “the option to 106 
report other symptoms,” a strategy that does not reliably capture a complete clinical picture.15 A 107 
large study of infections in Iceland considered only the following symptoms compatible with 108 
COVID-19, “cough, fever, aches, and shortness of breath.”16 A report of individuals infected on 109 
the Diamond Princess cruise ship omitted commonly reported symptoms, including anosmia and 110 
gastrointestinal complaints, which might have led to an overestimated asymptomatic rate of 44% 111 
(311/712).11 Additionally, it is not clear how the language barrier was addressed, since symptom 112 
assessment occurred in Japan from a presumably multinational and multilingual cohort. Other 113 
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studies of the Diamond Princess outbreak have estimated different rates of asymptomatic 114 
infections, including a modeling study that estimated 18% (credible interval 16-20%) and 115 
another study of the early phase of the outbreak that reported 14% (24/172), but only tested 116 
“suspected cases” (defined as those with fever or respiratory symptoms) which might have 117 
biased the outcome.29,30  118 
 119 
Two detailed investigations of outbreaks at nursing facilities – one in Washington State and one 120 
in Illinois – from March 2020 did not include assessment for changes in smell or taste, since 121 
these symptoms were not widely recognised at that time.12,17,31 A study of an outbreak associated 122 
with a call centre in South Korea found that just 4% of nearly 100 cases were persistently 123 
asymptomatic, though the list of symptoms enquired about is not described in the report.9 Details 124 
about case definition and manner of symptom assessment are required to interpret study results 125 
and incomplete symptom assessment risks overestimate of the asymptomatic fraction. 126 
 127 
In describing the experience with the virus in the town of Vo, Italy, investigators reported a 128 
persistently asymptomatic fraction of 43%.13 Study participants were tested for SARS-CoV-2 by 129 
nasopharyngeal swab and received a survey with symptom assessment on February 24 and again 130 
on March 7, an interval of 12 days. Symptomatic cases were defined as those who “required 131 
hospitalization and/or reported fever (yes/no or a temperature above 37 degrees Celsius) and/or 132 
cough and/or at least two of the following symptoms: sore throat, headache, diarrhea, vomit, 133 
asthenia, muscle pain, joint pain, loss of taste or smell, shortness of breath.” While reported 134 
symptom assessment was systematic and comprehensive, requiring at least two minor symptoms 135 
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be present in cases confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) may 136 
have led to misclassification of some individuals with mild symptoms as asymptomatic. 137 
 138 
2. Inadequate follow up time 139 
An absence of symptoms at the time of a positive RT-PCR test is insufficient to determine 140 
whether an individual has persistently asymptomatic infection because an RT-PCR test result can 141 
be positive before symptom onset.3,32,33 Cross-sectional studies can therefore assess the 142 
proportion of people with and without symptoms at the time of testing but cannot distinguish 143 
pre-symptomatic from asymptomatic infection.  144 
 145 
The duration of follow up needed to capture pre-symptomatic individuals is the maximum 146 
duration of the incubation period, and over 95% of infected individuals who develop symptoms 147 
will do so within 14 days, making this a reasonable length of follow up to rule out the vast 148 
majority of pre-symptomatic cases.1 Two examples show the importance of follow-up time in 149 
studies with different contexts and inclusion criteria. Among residents of a nursing home in the 150 
USA who were tested after a health care worker was found to be infected, 48 tested positive for 151 
SARS-CoV-2, of whom 21 had symptoms and 27 were asymptomatic at the time of testing. Over 152 
the next seven days, 24 of the initial 27 without symptoms developed symptoms and were 153 
therefore pre-symptomatic at the time of testing.17 In South Korea, 110 of 303 individuals were 154 
initially asymptomatic at a clinical treatment centre, a setting designed for individuals with mild 155 
or no symptoms, and 21 eventually developed symptoms indicating a persistently asymptomatic 156 
fraction in this cohort of 29%.34  157 
 158 
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Three publications about pregnant women in New York City show the importance of accurate 159 
reporting of symptoms and adequate follow-up.14,35,36 The first report, stating that “29 of the 33 160 
patients who were positive for SARS-CoV-2 at admission (87.9%) had no symptoms of COVID-161 
19 at presentation,” had a median follow up time of two days post-partum, an insufficient period 162 
to exclude pre-symptomatic infection.14 In fact, two subsequent publications with an overlapping 163 
cohort of obstetric patients with longer follow up, found that the asymptomatic fraction was 164 
much lower, including one study where just 46/158 (29%) remained asymptomatic throughout 165 
follow up (63 were asymptomatic at diagnosis) and another study with at least two weeks of 166 
follow up time for patients where 4/43 (9%) remained asymptomatic (12 were asymptomatic at 167 
diagnosis).35,36  168 
 169 
Several other cross-sectional studies in different contexts have at times been interpreted 170 
inappropriately as reporting the asymptomatic fraction, including a study at Boston homeless 171 
shelters, a report of an outbreak on a cruise ship off South America, and a study of infections in 172 
Iceland, among others.10,15,16,37 Additionally, an RT-PCR test may remain positive after the 173 
period of infectiousness since the median duration of nasopharyngeal swab shedding is 22 174 
days.22 It is therefore also important to assess for prior symptoms if the timing of infection is 175 
unknown.  176 
 177 
3. Issues with assessment of symptom status in seroprevalence studies: 178 
Antibody test characteristics are defined by comparison with RT-PCR as a reference standard 179 
and we have insufficient understanding of their performance for RT-PCR-negative (or untested) 180 
individuals with prior asymptomatic infection. Antibody durability in these cases is another 181 
Towards an Accurate and Systematic Characterization of Persistently Asymptomatic Infection 
with SARS-CoV-2 
 9 
concern, with one study finding that among previously RT-PCR-positive individuals, 40% 182 
(12/30) of asymptomatic, but only 13% (4/31) of symptomatic individuals, became seronegative 183 
after about 8 weeks.38 184 
 185 
 A large seroprevalence study in Spain reported that nearly a third of people with SARS-CoV-2 186 
antibodies were asymptomatic.20 Symptom assessment was comprehensive and systematic and 187 
although there was no follow up period, those with positive IgG titres would have been out of the 188 
pre-symptomatic period.39 In the study, IgG antibodies were found in 8.0% (95% CI 6.0-10.6%) 189 
of participants with a prior negative RT-PCR test and in 4.2% (95% CI 3.8-4.5%) of those who 190 
never had an RT-PCR test. The authors suggest that those with a prior negative RT-PCR test 191 
might have received late RT-PCR testing in the setting of a compatible syndrome, but provide no 192 
evidence for this and this was not assessed in the study.20 To interpret these results properly, it 193 
would be important to understand the study population better; were these individuals tested 194 
because they indeed had a compatible syndrome and/or a close contact? In that case, they are 195 
likely true positives. However, it is important to consider the possibility that some or many of 196 
these individuals might be false positives. 197 
 198 
Why understanding the persistently asymptomatic fraction is important 199 
Gaps in our understanding limit development of optimal public health strategies to control the 200 
pandemic. For instance, we do not know whether people with persistently asymptomatic SARS-201 
CoV-2 infection have demographic, clinical, immunological or virologic characteristics that 202 
differ from those who develop symptoms, or how their transmission potential differs. Studies 203 
reporting on asymptomatic individuals with SARS-CoV-2 infection often include small numbers 204 
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of study participants, without detailed descriptions of baseline characteristics or comparison with 205 
participants with symptoms. This evidence gap precludes analyses of how asymptomatic 206 
individuals might differ from those who develop symptoms. More detailed descriptions would 207 
allow for a richer understanding of differences between these populations and pooled analyses 208 
would be possible if individual patient data were available. In future research studies, meticulous 209 
description of methods used to enrol participants and assess the persistently asymptomatic 210 
fraction will also make it easier to investigate study heterogeneity in systematic reviews of this 211 
topic,7 and better inform modelling studies that make assumptions about viral transmission 212 
dynamics based on estimates of the persistently asymptomatic fraction.40 This information will 213 
improve pandemic control strategies. 214 
 215 
Detailed follow-up of people with persistently asymptomatic SARS-CoV-2 infection will also 216 
allow a definitive understanding of viral dynamics and antibody responses in these individuals, 217 
which could help determine whether they develop a sufficiently robust and durable antibody 218 
response after infection and how they will respond to vaccines. Furthermore, the characteristics 219 
of this group may help explain the wide spectrum of illness severity and COVID-19 220 
pathogenesis. Lastly, with a growing understanding that mild symptoms may be associated with 221 
SARS-CoV-2 infection coupled with lower barriers to diagnostic testing, more cases could be 222 
readily identified and help reduce community transmission. 223 
 224 
Recommendations 225 
We make six recommendations to allow for accurate ascertainment of asymptomatic infection 226 
status and eventually define the asymptomatic fraction.  227 




1. Define persistently asymptomatic infection clearly 229 
The term “persistently asymptomatic SARS-CoV-2 infection” should be reserved for people who 230 
have no known COVID-19 symptoms, including no atypical or mild symptoms, throughout the 231 
course of infection. Cross-sectional studies should report proportions without symptoms as 232 
“asymptomatic at the time of testing.” 233 
 234 
2. Use a standard, broad symptom definition 235 
There are numerous clinical case definitions with emphasis on different symptoms from various 236 
groups including the World Health Organization, the European Centre for Disease Prevention 237 
and Control, the United States Centers for Disease Control and Prevention, and the Canadian 238 
Ministry of Health and Long-term Care, (Table 2). We recommend standardisation of clinical 239 
definitions and favour the symptom list in the Canadian case definition at this time, which is the 240 
most comprehensive. This definition allows documentation of the most common symptoms, and 241 
characterisation of cases as typical, atypical, mildly symptomatic, or persistently asymptomatic. 242 
 243 
[Table 2] 244 
 245 
3. Assess symptoms prospectively and retrospectively for the minimum appropriate 246 
follow up period 247 
A minimum follow-up period of 14 days from last possible exposure (or first positive test if 248 
exposure is unknown) will differentiate pre-symptomatic from persistently asymptomatic 249 
individuals. Investigators should report the follow-up period, together with baseline 250 
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characteristics of individuals with all clinical presentations, including age, gender and ethnic 251 
group as a minimum.  252 
 253 
An investigation of non-hospitalised household contacts of individuals with SARS-CoV-2 254 
infection in Wisconsin and Utah performed an assessment consistent with our recommendations, 255 
including with systematic, detailed symptom assessment and adequate follow up period, and may 256 
be a model for similar studies moving forward.41 257 
 258 
4. Clearly report testing protocols used for SARS-CoV-2 detection 259 
Details of testing, including timing, site, and test platform are necessary to interpret results from 260 
studies reporting on asymptomatic cases. Timing of testing should reflect the SARS-CoV-2 viral 261 
load dynamics and incubation period and not be done prior to day five after exposure for those 262 
without symptoms.42 The optimal site of testing is actively being studied but most clinical 263 
experience to date is with nasopharyngeal or oropharyngeal testing. Salivary testing might be 264 
less sensitive and may have other handling constraints (i.e. rapid time to processing) that require 265 
further study.43 Poor sampling may yield false negative results. This was suggested in the report 266 
of four symptomatic individuals from Italy who initially had negative nasopharyngeal RT-PCR 267 
tests which were positive when a repeat sample was obtained by an otolaryngologist 6-72 hours 268 
later.44 In another study, suspected false negative RT-PCR tests had significantly lower amounts 269 
of human DNA compared with other samples.45 While RT-PCR based platforms are most 270 
commonly used now, less sensitive rapid antigen testing is likely to become much more 271 
common.46 The sensitivity of antigen tests for persistently asymptomatic cases is unknown at this 272 
time. 273 




5. Detailed reporting of serologic studies to understand for asymptomatic infection 275 
Serologic testing could become a helpful adjunct to define the persistently asymptomatic 276 
fraction. To interpret results, researchers should clearly report the time window between 277 
suspected infection and antibody testing. Symptom recall bias may be worse with longer delays. 278 
In a follow up of the Iceland study, researchers clearly reported the timing of exposures and 279 
antibody testing.16,47 They found 10% (142/1421) of those quarantined after a COVID-19 280 
exposure had detectable antibodies without prior symptoms and without reported PCR testing.47 281 
The pretest probability for infection is higher in quarantined individuals compared with a random 282 
population sample and, though this study did not estimate the population wide asymptomatic 283 
fraction, it improves on prior serologic studies assessment of asymptomatic cases. Serial testing 284 
can help define antibody decay trajectories, an important variable for estimating the 285 
asymptomatic fraction from serological studies. 286 
 287 
6. Design studies to minimise biases that affect ascertainment of the asymptomatic 288 
fraction 289 
 Research studies to measure the persistently asymptomatic fraction of SARS-CoV-2 infection 290 
need to be designed so that the absence or presence of symptoms does not affect selection into 291 
the study. The ideal study design would screen a population and follow those infected with 292 
SARS-CoV-2 prospectively. Clinical and demographic data would be collected at baseline, with 293 
frequent (even daily) comprehensive symptom assessments, serial RT-PCR testing from multiple 294 
body sites and intermittent measurements of antibody titres and immune response. Detailed 295 
contact tracing studies in unbiased populations should also be done so that secondary attack rates 296 
Towards an Accurate and Systematic Characterization of Persistently Asymptomatic Infection 
with SARS-CoV-2 
 14 
can be compared between people with persistently asymptomatic and symptomatic infection, and 297 
the duration of their period of infectiousness can be determined. 298 
  299 
The distinction between asymptomatic and pre-symptomatic individuals should not distract from 300 
the overwhelming evidence that individuals without symptoms can transmit the virus , usually 301 
when they are pre-symptomatic, emphasising the need to continue implementing non-302 
pharmaceutical interventions such as physical distancing, universal masking and handwashing.2 303 
In addition, testing policy in outbreak settings and high-risk environments such as long-term 304 
health care facilities needs to reflect this critical fact: individuals without symptoms in close 305 
contact with an index case will need to be tested as part of the outbreak investigation to identify 306 
cases and allow for effective control measures. 307 
 308 
To date, absence of comprehensive understanding about asymptomatic SARS-CoV-2 infection 309 
makes it difficult to inform public health strategies on the best way to control the pandemic. 310 
Uncertainty about the existence, characteristics, prognosis and role of asymptomatic SARS-CoV-311 
2 infection in this pandemic will continue unless we have systematically and accurately collected 312 
data. 313 
  314 
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Setting [Ref] Asymptomatic 
% reported 
Follow-up period Symptom assessment Notes 
1. Incomplete symptom reporting or restrictive symptom assessment 
Diamond 
Princess 
cruise ship 11 
311/712 (44%) Adequate “cough, dyspnoea, chest 






facility in the 
US 12 
13/33 (39%) Adequate “typical (fever, cough, 
shortness of breath, 
hypoxia) and atypical (sore 
throat, nasal congestion, 
diarrhoea, decreased 
appetite, chills, myalgias, 
headaches, new onset 
confusion) symptoms” 
Authors note that 
memory impairment 
may have resulted in 
an overestimate in 
asymptomatic rate  
Call centre in 
South Korea 9 
4/97 (4.1%) Adequate Not defined Face-to-face 
interviews for 
symptom assessment 
Vo, Italy 13 42.5% (95% CI 
31.5% - 54.6%) 
with a total of 81 
cases 











Inadequate “Fever or other symptoms 
of COVID-19” 




follow up period 




129/147 (87.8%) Inadequate Cough, shortness of breath, 
other symptoms optional 
Single time point 
symptom screen 
Iceland 16 525/1221 (43%) Inadequate “cough, fever, aches, and 
shortness of breath” 








on day 1 and day 7 





in US 18 
257/631 (40.7%) Inadequate Comprehensive Symptom assessments 




44/238 (18.5%) Not well defined Comprehensive Convenience sample; 
retrospective 
symptom assessment 
3. Serological study 
Spain 20 21.9 (95% CI 19.1 
– 24.9) to 35.8 
(95% CI 33.1 – 




Single time point but 
serological survey 
“fever, chills, severe 
tiredness, sore throat, 
cough, 
shortness of breath, 
headache, anosmia or 
ageusia” 
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Table 1: Assessment of selected studies reporting the asymptomatic fraction 
 315 
  316 
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Source Symptom Citation 
World Health 
Organization 
Fever AND cough 
OR 
Three or more of the following: fever, cough, general weakness/fatigue, 
headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, 
diarrhea, altered mental status 
OR 
Recent onset anosmia or ageusia without another explanation 
https://www.who.int/publications/i/item/WHO-2019-
nCoV-Surveillance_Case_Definition-2020.1 (accessed 






At least one of the following symptoms: cough, fever, shortness of breath, or 
sudden onset anosmia, ageusia or dysgeusia 
https://www.ecdc.europa.eu/en/covid-




Control of the 
USA 
At least two of the following symptoms: fever, chills, rigors, myalgia, 
headache, sore throat, nausea or vomiting, diarrhea, fatigue, congestion or 
runny nose 
OR 
Any one of the following: cough, shortness of breath, difficulty breathing, 
new olfactory disorder, new taste disorder 
https://wwwn.cdc.gov/nndss/conditions/coronavirus-
disease-2019-covid-19/case-definition/2020/08/05/ 








Any of the following: 
Common symptoms: fever, new or worsening cough, shortness of breath 
Other symptoms: sore throat, difficulty swallowing, new olfactory disorder, 
nausea/vomiting, diarrhea, abdominal pain, runny nose or nasal congestion 
(in the absence of underlying reason for these symptoms such as seasonal 
allergies, postnasal drip, etc.) 
Atypical symptoms: unexplained fatigue/malaise, myalgias, delirium, 
unexplained or increased number of falls, acute functional decline, 









(accessed September 7, 2020)  
Table 2: Symptoms considered consistent with COVID-19 from various case definitions 
 317 
  318 
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